(TMCI) Treace Medical Concepts - Ratings and Ratios
Medical Devices, Bunion Correction System, Surgical Instruments, Implants
TMCI EPS (Earnings per Share)
TMCI Revenue
Description: TMCI Treace Medical Concepts
Treace Medical Conceptscepts, Inc. (NASDAQ: TCBI) is a a medical technology company specializing in the design development, and marketing of innovative medical devices for foot and ankle surgery, specifically the Lapiplasty 3D bun correction system, a 3D bunion correction system that address the root cause of of the deformity. The companys product portfolio includes the Lapiplastyplasty system, Adductoplasty system, and L incision system, catering to physicians, surgeons, ambulatory surgery centers centers, and hospitals.
From a financial perspective, TCBI has a market capitalization of approximately $369.88 million. Given the companys negative return on equity ( -48.69%), it is likely experiencing significant losses. To gauge the companys financial health, key performance indicators (KPIs) such as revenue growth rate, gross margin, operating expenses as a percentage of revenue, and operating cash flow can be analyzed. Additionally, the companys to evaluate the sustainability of the business model.
The stock has experienced significant volatility, with a 52-week high of $10.54 and a low of $44.66., and an average true range (ATR) of of 4.87%. %,. Key technical indicators include the short-term moving averages (SMA20: $5.85 and SMA50: $6. 30) and the long-term SMA200: $77.25). These metrics can be used to to assess the stocks trend and potential future price movements.
To make an informed investment informed, it is crucial to analyze the companys competitive landscape, growth prospects, and valuation multiples. A thorough examination of these factors will provide insights into the companys value proposition and potential investment opportunities.
TMCI Stock Overview
| Market Cap in USD | 458m |
| Sub-Industry | Health Care Equipment |
| IPO / Inception | 2021-04-23 |
TMCI Stock Ratings
| Growth Rating | -39.7% |
| Fundamental | 22.2% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | 14.0% |
| Analyst Rating | 3.57 of 5 |
TMCI Dividends
Currently no dividends paidTMCI Growth Ratios
| Growth Correlation 3m | 70.5% |
| Growth Correlation 12m | -4.1% |
| Growth Correlation 5y | -82.9% |
| CAGR 5y | -32.79% |
| CAGR/Max DD 3y | -0.39 |
| CAGR/Mean DD 3y | -0.52 |
| Sharpe Ratio 12m | -0.70 |
| Alpha | 0.13 |
| Beta | 0.583 |
| Volatility | 61.79% |
| Current Volume | 271.6k |
| Average Volume 20d | 310.8k |
| Stop Loss | 6.6 (-6.3%) |
| Signal | -0.45 |
Piotroski VR‑10 (Strict, 0-10) 1.5
| Net Income (-49.2m TTM) > 0 and > 6% of Revenue (6% = 12.8m TTM) |
| FCFTA -0.24 (>2.0%) and ΔFCFTA -3.26pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 49.45% (prev 64.02%; Δ -14.57pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.07 (>3.0%) and CFO -14.9m > Net Income -49.2m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 3.52 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (63.0m) change vs 12m ago 1.49% (target <= -2.0% for YES) |
| Gross Margin 80.12% (prev 80.67%; Δ -0.55pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 98.84% (prev 87.81%; Δ 11.02pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -8.35 (EBITDA TTM -34.5m / Interest Expense TTM 5.26m) >= 6 (WARN >= 3) |
Altman Z'' -3.69
| (A) 0.51 = (Total Current Assets 147.6m - Total Current Liabilities 41.9m) / Total Assets 206.4m |
| (B) -1.08 = Retained Earnings (Balance) -223.3m / Total Assets 206.4m |
| warn (B) unusual magnitude: -1.08 — check mapping/units |
| (C) -0.20 = EBIT TTM -43.9m / Avg Total Assets 216.3m |
| (D) -2.05 = Book Value of Equity -223.2m / Total Liabilities 108.8m |
| Total Rating: -3.69 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 22.18
| 1. Piotroski 1.50pt = -3.50 |
| 2. FCF Yield -10.95% = -5.0 |
| 3. FCF Margin -22.81% = -7.50 |
| 4. Debt/Equity 0.58 = 2.34 |
| 5. Debt/Ebitda -1.64 = -2.50 |
| 6. ROIC - WACC (= -35.12)% = -12.50 |
| 7. RoE -46.76% = -2.50 |
| 8. Rev. Trend 53.60% = 4.02 |
| 9. EPS Trend -13.46% = -0.67 |
What is the price of TMCI shares?
Over the past week, the price has changed by +0.57%, over one month by +0.00%, over three months by +29.41% and over the past year by +35.12%.
Is Treace Medical Concepts a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of TMCI is around 5.77 USD . This means that TMCI is currently overvalued and has a potential downside of -18.04%.
Is TMCI a buy, sell or hold?
- Strong Buy: 2
- Buy: 0
- Hold: 5
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the TMCI price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 8.6 | 21.9% |
| Analysts Target Price | 8.6 | 21.9% |
| ValueRay Target Price | 6.4 | -9.4% |
Last update: 2025-09-05 05:04
TMCI Fundamental Data Overview
CCE Cash And Equivalents = 69.3m USD (Cash And Short Term Investments, last quarter)
P/S = 2.1427
P/B = 4.692
Beta = 0.682
Revenue TTM = 213.8m USD
EBIT TTM = -43.9m USD
EBITDA TTM = -34.5m USD
Long Term Debt = 53.5m USD (from longTermDebt, last quarter)
Short Term Debt = 3.20m USD (from shortTermDebt, last quarter)
Debt = 56.7m USD (Calculated: Short Term 3.20m + Long Term 53.5m)
Net Debt = 5.38m USD (from netDebt column, last quarter)
Enterprise Value = 445.4m USD (458.0m + Debt 56.7m - CCE 69.3m)
Interest Coverage Ratio = -8.35 (Ebit TTM -43.9m / Interest Expense TTM 5.26m)
FCF Yield = -10.95% (FCF TTM -48.8m / Enterprise Value 445.4m)
FCF Margin = -22.81% (FCF TTM -48.8m / Revenue TTM 213.8m)
Net Margin = -23.01% (Net Income TTM -49.2m / Revenue TTM 213.8m)
Gross Margin = 80.12% ((Revenue TTM 213.8m - Cost of Revenue TTM 42.5m) / Revenue TTM)
Tobins Q-Ratio = -2.00 (set to none) (Enterprise Value 445.4m / Book Value Of Equity -223.2m)
Interest Expense / Debt = 2.33% (Interest Expense 1.32m / Debt 56.7m)
Taxrate = 21.0% (US default)
NOPAT = -43.9m (EBIT -43.9m, no tax applied on loss)
Current Ratio = 3.52 (Total Current Assets 147.6m / Total Current Liabilities 41.9m)
Debt / Equity = 0.58 (Debt 56.7m / last Quarter total Stockholder Equity 97.6m)
Debt / EBITDA = -1.64 (Net Debt 5.38m / EBITDA -34.5m)
Debt / FCF = -1.16 (Debt 56.7m / FCF TTM -48.8m)
Total Stockholder Equity = 105.2m (last 4 quarters mean)
RoA = -23.82% (Net Income -49.2m, Total Assets 206.4m )
RoE = -46.76% (Net Income TTM -49.2m / Total Stockholder Equity 105.2m)
RoCE = -27.69% (Ebit -43.9m / (Equity 105.2m + L.T.Debt 53.5m))
RoIC = -27.66% (NOPAT -43.9m / Invested Capital 158.8m)
WACC = 7.46% (E(458.0m)/V(514.7m) * Re(8.16%)) + (D(56.7m)/V(514.7m) * Rd(2.33%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 100.00 | Cagr: 1.17%
Discount Rate = 8.16% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow -48.8m)
EPS Correlation: -13.46 | EPS CAGR: -26.92% | SUE: 0.36 | # QB: 0
Revenue Correlation: 53.60 | Revenue CAGR: 13.99% | SUE: 0.28 | # QB: 0
Additional Sources for TMCI Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle